GSK Shares Climb on Positive Lung Cancer Drug Trial Results

By EC Assets · Published 14 September 2026

GSK shares increased after the company released positive data from a lung cancer drug trial. The company's stock rose 2.5%. GSK is accelerating investment in research and development. It is expanding its late-stage pipeline. The company is targeting cost savings of £1.9 billion. These savings are intended to support product launches. They also aim to maintain profitability through upcoming HIV patent expirations. Chief Financial Officer Julie Brown discussed these plans during a company presentation. The pharmaceutical firm is advancing its experimental seasonal influenza vaccine into late-stage development. This follows encouraging mid-stage results. The mRNA-based candidate generated stronger immune responses than currently approved flu vaccines in both younger and older adults. Its design targets two important surface proteins on the influenza virus. GSK plans to stop manufacturing at its Dresden, Germany flu vaccine site. This change is scheduled for summer 2027. Healthcare stocks broadly declined late Tuesday afternoon. The NYSE Healthcare Index fell 2.5%. The State Street Health Care Select Sector SPDR ETF dropped 2.2%. This article is intended for informational purposes only. It does not constitute investment advice.